CHINA HUAJUN GP(00377): General authorization for subscribing new shares is invalid.
Chinese Hua Jun (00377) announced that the subscription matters must be completed by May 31, 2026, or before reaching the conditions of the subscription agreement. As of the date of this announcement, several conditions of the subscription matters have not been fully met, so the subscription agreement has accordingly become invalid.
China Huajun GP (00377) announced that the subscription matter must be completed by May 31, 2026, or before reaching the conditions set forth in the subscription agreement. As of the date of this announcement, several conditions of the subscription matter have not been fully met, therefore, the subscription agreement has become void accordingly.
Related Articles
.png)
LIVZON PHARMA (01513): The application for market approval of Lecanikta monoclonal antibody injection has been accepted by the National Medical Products Administration.
Yuanheng Gas (00332) plans to carry out a share capital restructuring.
HUANENG POWER (00902) A-share trading abnormal fluctuations do not exist major issues that should be disclosed but have not been disclosed.
LIVZON PHARMA (01513): The application for market approval of Lecanikta monoclonal antibody injection has been accepted by the National Medical Products Administration.
Yuanheng Gas (00332) plans to carry out a share capital restructuring.
HUANENG POWER (00902) A-share trading abnormal fluctuations do not exist major issues that should be disclosed but have not been disclosed.
